Last updated: September 7, 2026
Prasterone is a niche menopausal-health drug marketed in the United States as Intrarosa, a 6.5 mg vaginal insert for moderate-to-severe dyspareunia caused by vulvar and vaginal atrophy. The product has a differentiated non-estrogen positioning but operates in a crowded, largely generic vaginal-estrogen market. Its commercial ceiling is constrained by a narrow labeled indication, daily administration, reimbursement friction, and limited public disclosure of standalone sales.
The near-term market outlook is stable rather than high-growth. The principal commercial risks are generic entry under an abbreviated new drug application, payer substitution toward lower-cost vaginal estrogen, and continued patient migration toward over-the-counter moisturizers or compounded products. Patent protection may extend well beyond FDA regulatory exclusivity, but the practical value of those patents depends on Orange Book listings, claim scope, and the outcome of any future Paragraph IV litigation.
What is prasterone and how is Intrarosa used?
Prasterone is dehydroepiandrosterone, or DHEA, administered locally in the vagina. Intrarosa is inserted once daily at bedtime. The FDA-approved indication is the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. The approved product is not labeled for systemic menopausal symptoms, osteoporosis prevention, or general vaginal dryness outside the indicated condition.[1]
What differentiates prasterone from vaginal estrogen?
After vaginal administration, prasterone is converted locally into estrogenic and androgenic metabolites. Its marketing position is based on local activity and limited systemic exposure rather than an absence of estrogenic pharmacology.
| Product category |
Representative products |
Active ingredient |
Typical positioning |
| Vaginal prasterone |
Intrarosa |
Prasterone 6.5 mg |
Dyspareunia associated with menopause |
| Vaginal tablet |
Vagifem, generic estradiol |
Estradiol |
Genitourinary syndrome of menopause |
| Vaginal insert |
Imvexxy, generic estradiol where available |
Estradiol |
Low-dose local estrogen therapy |
| Vaginal cream |
Estrace, Premarin, generics |
Estradiol or conjugated estrogens |
Broad vaginal atrophy treatment |
| Oral non-estrogen therapy |
Osphena |
Ospemifene |
Dyspareunia and vaginal atrophy |
| OTC products |
Moisturizers and lubricants |
Nonprescription ingredients |
Symptom relief without prescription drug status |
Intrarosa's regulatory and commercial distinction is strongest among patients and prescribers seeking a local non-estrogen prescription option. Its differentiation is weaker when payers evaluate clinical outcomes against generic estradiol products.
When did prasterone receive FDA approval?
The FDA approved Intrarosa on November 17, 2016, under NDA 208470.[1] The approval followed clinical studies evaluating vaginal prasterone in postmenopausal women with moderate-to-severe dyspareunia.
The product's FDA regulatory timeline is:
| Event |
Date |
| FDA approval of Intrarosa |
November 17, 2016 |
| Dosage form |
6.5 mg vaginal insert |
| Administration |
One insert daily at bedtime |
| Approved use |
Moderate-to-severe dyspareunia due to menopause |
| Regulatory pathway |
New drug application |
| Likely regulatory exclusivity type |
Clinical-investigation exclusivity associated with approval, subject to FDA records |
| Current commercial issue |
Patent term, generic filing, reimbursement, and prescriber adoption |
FDA regulatory exclusivity and patent protection are separate. FDA exclusivity can block approval of a competing application for a defined period, while patents can block commercial marketing for the duration of enforceable claims. A drug can lose FDA exclusivity while retaining patent protection.
How large is the prasterone market?
Prasterone is a small segment of the broader genitourinary syndrome of menopause market. Public sources do not provide a reliable, audited global market total for prasterone alone. Commercial market reports often combine prasterone with vaginal estrogen, hormone-replacement products, or broader women's-health categories, producing estimates that are not directly comparable.
The addressable market is defined by several filters:
- Postmenopausal women with vulvovaginal atrophy symptoms.
- Patients whose principal complaint includes dyspareunia.
- Patients requiring prescription treatment.
- Patients and clinicians willing to use a daily vaginal insert.
- Patients whose insurance coverage supports the product relative to generic alternatives.
The total population with genitourinary syndrome of menopause is materially larger than the treated population for prescription prasterone. The commercial opportunity therefore depends more on diagnosis, treatment initiation, persistence, and reimbursement than on epidemiological prevalence alone.
What limits prasterone's market expansion?
The main constraints are:
- Generic vaginal estradiol is usually less expensive.
- Vaginal estrogen has broad clinical familiarity and multiple dosage forms.
- Intrarosa requires daily administration.
- The indication is narrower than the broader symptom complex of genitourinary syndrome of menopause.
- Payers can impose prior authorization or step therapy.
- Some patients prefer OTC lubricants and moisturizers.
- The product's local hormonal mechanism can still create prescribing concerns among patients with hormone-sensitive cancer histories, despite its distinct labeling.
These factors support a defensible specialty niche but make rapid share expansion difficult without significant payer access improvements or a broader label.
What is the financial trajectory of prasterone?
Standalone Intrarosa revenue is not consistently disclosed in public company filings. The product has changed commercial ownership and licensing arrangements, making historical revenue comparisons difficult. Public financial reporting generally aggregates women's-health products or reports portfolio-level sales rather than Intrarosa-specific net revenue.
The financial trajectory is best characterized as follows:
| Period |
Commercial interpretation |
| 2016-2018 |
Launch and market-education phase; limited prescriber familiarity and reimbursement development |
| 2019-2021 |
Expansion of awareness in vaginal atrophy and dyspareunia; continuing competition from established vaginal estrogen products |
| 2022 onward |
Portfolio-ownership changes increased the importance of licensing economics, sales-force allocation, and payer management |
| Medium term |
Mature niche-product profile with revenue dependent on retention, price realization, and generic timing |
Revenue quality is likely more important than headline prescription growth. A specialty women's-health product can generate attractive gross margins if manufacturing costs are low and price realization is maintained. Net sales can still weaken when insurers require generic estradiol first or when specialty pharmacies and wholesalers demand higher discounts.
Which financial indicators matter most?
For prasterone, investors and licensors should monitor:
- Annual and quarterly prescription volume.
- New-to-brand prescriptions versus refill volume.
- Persistence after the first prescription.
- Gross-to-net deductions.
- Commercial insurance coverage.
- Medicaid and Medicare Part D treatment.
- Average realized price per insert.
- Specialty-pharmacy concentration.
- Sales and marketing expense per new patient.
- Generic application activity.
- Royalty or milestone obligations under licensing agreements.
Because public standalone revenue is limited, prescription claims data and payer coverage studies are more useful than corporate revenue disclosures for measuring demand.
What patents protect prasterone and Intrarosa?
The central U.S. patent estate has historically focused on vaginal administration of prasterone and treatment of vulvovaginal atrophy or related symptoms. Public patent records include U.S. Patent No. 9,266,951, associated with prasterone vaginal treatment claims.[2] The relevant commercial analysis must distinguish composition, formulation, dosage, and method-of-use claims.
| Protection category |
Commercial relevance |
| Active-ingredient claims |
Limited if the molecule is old or known |
| Vaginal-use claims |
Can protect use for menopausal atrophy or dyspareunia |
| Formulation claims |
Can protect the insert, excipients, release profile, or physical properties |
| Dosage claims |
Can distinguish the 6.5 mg daily regimen |
| Manufacturing claims |
May increase development cost for a generic but rarely prevents all substitution |
| Device or applicator claims |
Can add incremental protection where the product depends on a specialized delivery system |
The effective patent expiry date is not the same as the issuance date. It depends on the earliest effective nonprovisional filing date, terminal disclaimers, patent-term adjustment, patent-term extension, and the exact claim set listed in the FDA Orange Book.
What is the Orange Book status of Intrarosa?
Intrarosa is approved under NDA 208470 and is subject to FDA Orange Book analysis as a prescription drug product.[1,3] Orange Book-listed patents can require a generic applicant to make a Paragraph IV certification or wait until the relevant patent expires.
The commercial significance of an Orange Book listing depends on whether:
- The patent claims the approved product or method of use.
- The generic applicant must certify against the patent.
- The NDA holder can invoke a 30-month stay after receiving a Paragraph IV notice.
- The patent survives invalidity and noninfringement challenges.
- The listed patent remains enforceable and properly linked to the approved labeling.
A patent not listed in the Orange Book may still be relevant in district-court litigation, but it may not create the same regulatory delay as a listed patent.
When does prasterone lose exclusivity?
Prasterone does not have a single exclusivity date. Its market exclusivity has several components:
| Exclusivity type |
Effect |
| FDA clinical exclusivity |
Temporarily restricts approval of certain competing applications |
| Orange Book patent protection |
Can delay or block commercial generic entry |
| Non-listed patent rights |
May support litigation but do not necessarily create an FDA approval block |
| Trade secrets |
Can protect manufacturing know-how without preventing independent development |
| Brand equity |
May preserve demand after legal exclusivity ends |
The original FDA exclusivity period associated with approval is separate from patent protection and should not be treated as the expected generic-entry date. The relevant launch date will depend on the earliest viable generic filing, patent certifications, litigation, settlement terms, and the possibility of an authorized generic.
What generic entry risks exist?
The primary generic risk is a 505(j) abbreviated new drug application. A generic developer would likely need to demonstrate pharmaceutical equivalence, bioequivalence, and compliance with the reference product's labeling and dosage form requirements.
Potential technical barriers include:
- Vaginal insert manufacturing.
- Content uniformity at low dose.
- Stability and packaging.
- Dissolution or release characteristics.
- Applicator compatibility.
- Local delivery performance.
- Development of an equivalent formulation without infringing formulation claims.
These barriers are meaningful but do not create biologic-level protection. Prasterone is a small molecule, and the product is not a biologic. Biosimilar risk is therefore not applicable. The relevant threat is generic substitution, not biosimilar substitution.
Which companies compete with prasterone?
The competitive landscape includes branded pharmaceutical companies, generic manufacturers, women's-health specialists, and OTC suppliers.
| Competitor group |
Examples |
Competitive pressure |
| Generic vaginal estrogen |
Generic estradiol tablets, creams, and inserts |
Strong price pressure |
| Branded vaginal estrogen |
Imvexxy, Vagifem, Estrace, Premarin |
Strong clinical familiarity and formulation choice |
| Non-estrogen prescription therapy |
Osphena |
Differentiated oral option |
| Compounded hormone products |
Compounding pharmacies |
Price and customization, with regulatory and quality differences |
| OTC products |
Lubricants and moisturizers |
Substitution for mild or intermittent symptoms |
Prasterone's strongest competitive position is against patients who want a prescription vaginal therapy but prefer to avoid a conventional estrogen product. Its weakest position is against low-cost generic estradiol when payers use step therapy.
What licensing deals and ownership changes affect prasterone?
Commercial rights have involved Endoceutics, the product's original developer, and subsequent commercial partners. Mayne Pharma became a significant U.S. commercial participant in women's health, including Intrarosa, before later portfolio transactions changed the ownership and commercialization structure.[4,5]
Licensing analysis should focus on:
- Territory-specific rights.
- Upfront payments and milestone obligations.
- Royalty rates.
- Minimum sales or commercialization commitments.
- Manufacturing responsibilities.
- Rights after termination.
- Patent-prosecution control.
- Responsibility for Paragraph IV litigation.
- Inventory and supply obligations after a transaction.
A portfolio transfer can change the product's financial profile even when prescription demand is unchanged. A smaller owner may reduce promotional spending and preserve cash, while a larger women's-health platform may improve payer contracting and cross-selling.
What patent litigation and settlement risks affect prasterone?
A future Paragraph IV challenge would likely focus on one or more of the following:
- Invalidity of method-of-use claims.
- Noninfringement of formulation or dosage claims.
- Obviousness based on prior vaginal DHEA or hormone-treatment disclosures.
- Written-description or enablement challenges.
- Patent-listing scope.
- Regulatory carve-outs for protected indications.
A Paragraph IV notice could trigger a patent lawsuit and a statutory 30-month stay of FDA approval in certain circumstances.[3] Settlement outcomes could include:
- Delayed generic entry.
- A licensed generic.
- An authorized generic.
- A launch limited to non-protected indications.
- Royalty-bearing entry.
- No-agreement litigation resolution.
The economic effect of settlement depends on the entry date and whether multiple generic applicants receive the same or different launch rights. One early generic can materially reduce price, while several simultaneous entrants generally create a sharper decline.
How does prasterone compare with competing vaginal therapies?
| Factor |
Prasterone |
Generic vaginal estradiol |
| Molecule |
DHEA |
Estradiol |
| Main approved use |
Dyspareunia due to menopause |
Vaginal atrophy-related conditions, depending on product |
| Administration |
Daily vaginal insert |
Cream, tablet, insert, or ring |
| Cost position |
Typically branded or specialty-priced |
Usually lower |
| Generic substitution |
Future 505(j) risk |
Already established for several forms |
| Patient differentiation |
Non-estrogen positioning |
Familiar and widely used |
| Payer leverage |
Vulnerable to step therapy |
Usually favored by formulary economics |
| Patent risk |
Product and method patents |
Product-specific, often mature patent estates |
Prasterone can retain commercial relevance even after generic competition if it maintains a clear patient preference, favorable persistence, and formulary access. The product is less likely to become a broad first-line therapy across the full vaginal-atrophy market.
What generic launch scenarios are most likely?
Three scenarios are commercially relevant:
- Delayed generic entry. Patents withstand challenge or settlement pushes entry toward the end of the enforceable term. Brand pricing remains relatively stable.
- Single authorized or licensed generic. The sponsor controls some erosion and retains supply economics, but net revenue declines.
- Multiple independent generics. Price and market share decline rapidly, with the brand retaining only patients with strong product preference or favorable coverage.
The highest-value defense is usually a credible, enforceable patent position combined with sustained payer access. Marketing alone is unlikely to offset broad generic substitution in a price-sensitive vaginal-therapy category.
Key Takeaways
- Prasterone is a niche prescription treatment for menopausal dyspareunia, marketed in the U.S. as Intrarosa.
- Its commercial differentiation comes from local vaginal DHEA delivery and non-estrogen positioning.
- Generic vaginal estradiol is the main economic threat.
- Public companies have not consistently disclosed standalone Intrarosa revenue, limiting precise financial modeling.
- The product's FDA exclusivity period is distinct from its patent term and should not be used as the expected generic-entry date.
- Prasterone faces generic, not biosimilar, competition.
- Patent value depends on method-of-use, formulation, dosage, and Orange Book listing status.
- Payer coverage, refill persistence, and net pricing are more important than the total prevalence of genitourinary syndrome of menopause.
- Ownership and licensing changes can materially alter sales investment, royalties, and litigation strategy.
- Generic entry could produce a sharp revenue decline unless entry is delayed, licensed, or limited to a single competitor.
FAQs
Is prasterone the same as DHEA?
Yes. Prasterone is the pharmaceutical name for dehydroepiandrosterone, commonly abbreviated DHEA. Intrarosa uses a prescription vaginal formulation and should not be treated as equivalent to OTC DHEA supplements.
Is Intrarosa an estrogen product?
Intrarosa contains prasterone rather than estradiol. The drug is converted locally into estrogenic and androgenic metabolites, so its pharmacology differs from a direct vaginal estradiol product but is not hormonally inactive.
Can a generic manufacturer copy the Intrarosa vaginal insert?
A generic manufacturer may seek approval through the 505(j) pathway, but it must meet FDA pharmaceutical-equivalence and bioequivalence requirements and address any applicable Orange Book patents. Formulation and manufacturing patents may add development risk.
Does prasterone have biosimilar competition?
No. Prasterone is a small-molecule drug, not a biologic. The relevant regulatory pathway is an abbreviated new drug application for a generic product.
What is the main investment risk for prasterone?
The main risk is commercial erosion from generic vaginal estrogen and future prasterone generics. The severity will depend on patent durability, payer restrictions, refill persistence, net pricing, and the number and timing of competing launches.
References
- U.S. Food and Drug Administration. (2016). Intrarosa (prasterone) vaginal insert: Prescribing information. https://www.accessdata.fda.gov
- United States Patent and Trademark Office. (2016). U.S. Patent No. 9,266,951. https://patents.google.com
- U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
- Mayne Pharma Group Limited. (2021). Annual report. https://www.maynepharma.com
- Mayne Pharma Group Limited. (2022). Annual report. https://www.maynepharma.com
